Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial Meeting Abstract
| Authors: | Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; García-Gutierrez, V.; Mauro, M. J.; Leip, E.; Purcell, S.; Viqueira, A.; Brümmendorf, T. H. |
| Abstract Title: | Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301950 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7049 |
| Notes: | Meeting Abstract: 7049 -- This meeting was also held virtually -- Source: Wos |
